SCHEMBL17000014

SCHEMBL17000014

CNC(=O)c1cc(Oc2ccc(C(C)NC(=O)Nc3cc(C)ccc3OC)cc2)ccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
RAF1 P04049 5/20 0.59
DDR2 Q16832 1/20 0.51
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
KDR P35968 3/20 0.47
BRAF P15056 3/20 0.47
EPHX2 P34913 1/20 0.46
CSF1R P07333 1/20 0.45
GAA P10253 2/20 0.44
MEN1 O00255 2/20 0.44
TP53 P04637 2/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
MAPK14 Q16539 2/20 0.44
ABL1 P00519 2/20 0.44
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15575322 0.90 KMT2A (0.62) LMNARAF1DDR2KMT2AALDH1A1
SCHEMBL15574664 0.88 RAF1 (0.77) RAF1DDR2KMT2AKDRBRAF
SCHEMBL13603627 0.83 DDR2 (0.70) LMNARAF1DDR2KMT2AALDH1A1
SCHEMBL15573239 0.81 RAF1 (0.52) RAF1DDR2KMT2AKDRBRAF
SCHEMBL15574685 0.81 KMT2A (0.64) LMNARAF1DDR2KMT2AALDH1A1
SCHEMBL13603827 0.80 KDR (0.60) RAF1DDR2KMT2AKDRBRAF
SCHEMBL17000015 0.80 RAF1 (0.56) RAF1DDR2KMT2AKDRBRAF
SCHEMBL5429857 0.79 KMT2A (0.54) LMNARAF1DDR2KMT2AALDH1A1
SCHEMBL15573188 0.78 RAF1 (0.58) RAF1DDR2KMT2AKDRBRAF
SCHEMBL15573129 0.77 RAF1 (0.62) RAF1DDR2KMT2AKDRBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 LMNA 2196/4885RAF1 3072/4885DDR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.